CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Adrenal-to-brain (adrenal medullary) transplantation for Parkinson disease

This policy governs coverage determinations for adrenal medullary tissue transplantation to the corpus striatum (autograft or fetal allograft) to treat Parkinson's disease for Blue Cross Blue Shield - Rhode Island members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyAdrenal-to-brain (adrenal medullary) transplantation for Parkinson disease

Policy CodePolicy N/A

Change TypeNo material change

Effective DateFeb 6, 2010

Next Review DateN/A

Key ActionVerify member-specific coverage and benefits before proceeding; no prior authorization is required under this policy but benefits may vary by contract.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

MedicareAdvNot covered (Medicare Advantage)

CommercialNot medically necessary (Commercial)

S2103Procedure code not covered

AHRQ; AANKey evidence/guidance

Coverage Determinations

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage stances by product

Coverage determinations by product

Medicare Advantage: Adrenal-to-brain transplantation with autograft or fetal allograft is not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

Commercial Products: Adrenal-to-brain transplantation with autograft or fetal allograft is considered not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes.

Adrenal-to-brain transplantation (implantation of adrenal medullary tissue into striatal structures) — whether performed as an autograft (autotransplantation) or as a fetal allograft — is excluded / not medically necessary for the treatment of Parkinson disease. Coverage is determined by product type: for Medicare Advantage Plans the procedure is not covered, and for Commercial Products the procedure is considered not medically necessary because the evidence is insufficient to determine effects on health outcomes.

For Commercial Products, adrenal-to-brain transplantation using either autograft or fetal allograft approaches is considered not medically necessary. This determination is based on the conclusion that available evidence is insufficient to demonstrate benefit on health outcomes for individuals with Parkinson disease.

Provider Requirements and Billing Guidance

Prior Authorization

Prior authorization is not required for this service. Verify member-specific benefits and eligibility prior to providing services.

Prior authorization: Not applicable
Action: Verify member-specific benefits and eligibility

Denial Risk

Denial Triggers

Claims for adrenal-to-brain transplantation may be denied or considered not medically necessary depending on the member's plan type.

Medicare Advantage: Adrenal-to-brain transplantation with autograft or fetal allograft is not covered (insufficient evidence).
Commercial: Adrenal-to-brain transplantation with autograft or fetal allograft is considered not medically necessary (insufficient evidence).
Affected code example: S2103 (adrenal-to-brain transplantation)

Note

Benefit Verification

Refer to the member's Benefit Booklet, Evidence of Coverage (EOC), or Subscriber Agreement for specific coverage determinations and benefit limitations.

Benefits vary by group/contract — check the applicable Benefit Booklet / EOC / Subscriber Agreement.
Services may be classified as Not Medically Necessary or Not Covered depending on contract.

Documentation Required

Provider Action

Verify and document member eligibility, benefits, and coverage determination before rendering services to avoid claim denials.

Action: Confirm coverage and document the benefit verification in the claim/medical record.
Note: If benefit booklet or EOC indicates not covered or not medically necessary, claims will be denied accordingly.

Clinical Background

Adrenal medullary tissue transplantation to the corpus striatum was historically attempted to restore striatal dopamine and improve the motor and postural dysfunctions of Parkinson disease. Techniques included simultaneous adrenalectomy with implantation of adrenal medullary tissue fragments (autograft/autotransplantation) or implantation of adrenal tissue harvested from a fetus (fetal allograft). Implantation sites reported in the literature included striatal structures such as the caudate nucleus and putamen, performed via open microsurgical or stereotactic approaches.

Published data on these procedures are limited. Prior systematic reviews and professional society assessments have found insufficient evidence of efficacy and raised safety concerns, leading to the conclusion that adrenal-to-brain transplantation does not have established clinical benefit for Parkinson disease.

Key Definitions

Autograft (autotransplantation)

TermAutograft (autotransplantation)

DefinitionSimultaneous adrenalectomy and craniotomy with implantation of adrenal medullary tissue fragments into striatal structures (e.g., caudate nucleus or putamen).

Procedure detailsTissue is usually implanted in fragments into the caudate nucleus at the margin of the lateral ventricle (exposed to cerebrospinal fluid); fragments may be anchored with surgical staples or Gelfoam; open microsurgical or stereotactic techniques and implantation cannula may be used.

Allograft (fetal allograft)

TermAllograft (fetal allograft)

DefinitionHarvesting adrenal tissue from an aborted fetus and implanting it into striatal structures using similar surgical techniques as autografts.

Procedure detailsSurgical techniques mirror autograft methods (implantation into caudate or putamen via open microsurgical or stereotactic approaches).